Expleo Solutions Résultats passés
Passé contrôle des critères 2/6
Expleo Solutions has been growing earnings at an average annual rate of 25.8%, while the IT industry saw earnings growing at 20.4% annually. Revenues have been growing at an average rate of 31.9% per year. Expleo Solutions's return on equity is 15.4%, and it has net margins of 9.5%.
Informations clés
25.8%
Taux de croissance des bénéfices
16.1%
Taux de croissance du BPA
| IT Croissance de l'industrie | 24.3% |
| Taux de croissance des recettes | 31.9% |
| Rendement des fonds propres | 15.4% |
| Marge nette | 9.5% |
| Prochaine mise à jour des résultats | 14 Nov 2024 |
Mises à jour récentes des performances passées
Recent updates
Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 24
When Should You Buy Expleo Solutions Limited (NSE:EXPLEOSOL)?
Jun 21Investors Could Be Concerned With Expleo Solutions' (NSE:EXPLEOSOL) Returns On Capital
Mar 15The Returns On Capital At Expleo Solutions (NSE:EXPLEOSOL) Don't Inspire Confidence
Sep 15Increases to Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Might Cool off for now
Aug 19Calculating The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Jul 14Many Would Be Envious Of Expleo Solutions' (NSE:EXPLEOSOL) Excellent Returns On Capital
May 05A Look At The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Mar 15Expleo Solutions Limited's (NSE:EXPLEOSOL) Stock Been Rising: Are Strong Financials Guiding The Market?
Feb 15
Expleo Solutions (NSE:EXPLEOSOL) Knows How to Allocate Capital
Jan 24Introducing Expleo Solutions (NSE:EXPLEOSOL), A Stock That Climbed 76% In The Last Year
Jan 04A Look At The Intrinsic Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Dec 14Is There More To The Story Than Expleo Solutions's (NSE:EXPLEOSOL) Earnings Growth?
Nov 26Ventilation des recettes et des dépenses
Comment Expleo Solutions gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 9,919 | 942 | 0 | 0 |
| 31 Mar 24 | 9,649 | 904 | 23 | 0 |
| 31 Dec 23 | 9,405 | 1,038 | 16 | 0 |
| 30 Sep 23 | 9,305 | 1,251 | 16 | 0 |
| 30 Jun 23 | 9,152 | 1,311 | 16 | 0 |
| 31 Mar 23 | 9,033 | 1,339 | 16 | 0 |
| 31 Dec 22 | 5,072 | 823 | 6 | 0 |
| 30 Sep 22 | 4,779 | 648 | 6 | 0 |
| 30 Jun 22 | 4,439 | 583 | 6 | 0 |
| 31 Mar 22 | 7,425 | 677 | 9 | 0 |
| 31 Dec 21 | 3,703 | 463 | 4 | 0 |
| 30 Sep 21 | 3,366 | 475 | 4 | 0 |
| 30 Jun 21 | 3,131 | 490 | 4 | 0 |
| 31 Mar 21 | 3,009 | 504 | 4 | 0 |
| 31 Dec 20 | 2,971 | 534 | 4 | 0 |
| 30 Sep 20 | 2,931 | 512 | 4 | 0 |
| 30 Jun 20 | 2,852 | 475 | 4 | 0 |
| 31 Mar 20 | 2,702 | 399 | 4 | 0 |
| 31 Dec 19 | 2,627 | 353 | 28 | 0 |
| 30 Sep 19 | 2,614 | 298 | 28 | 0 |
| 30 Jun 19 | 2,741 | 345 | 28 | 0 |
| 31 Mar 19 | 2,865 | 362 | 28 | 0 |
| 31 Dec 18 | 2,973 | 372 | 27 | 0 |
| 30 Sep 18 | 2,949 | 377 | 27 | 0 |
| 30 Jun 18 | 2,898 | 313 | 27 | 0 |
| 31 Mar 18 | 2,764 | 320 | 27 | 0 |
| 31 Dec 17 | 2,583 | 256 | 573 | 0 |
| 30 Sep 17 | 2,488 | 243 | 573 | 0 |
| 30 Jun 17 | 2,475 | 230 | 573 | 0 |
| 31 Mar 17 | 2,599 | 238 | 29 | 0 |
| 31 Dec 16 | 2,747 | 293 | 402 | 0 |
| 30 Sep 16 | 2,809 | 329 | 402 | 0 |
| 30 Jun 16 | 2,790 | 372 | 402 | 0 |
| 31 Mar 16 | 2,642 | 369 | 402 | 0 |
| 31 Dec 15 | 2,445 | 279 | 290 | 0 |
| 30 Sep 15 | 2,312 | 271 | 290 | 0 |
| 30 Jun 15 | 2,212 | 240 | 290 | 0 |
| 31 Mar 15 | 2,142 | 216 | 391 | 0 |
| 31 Dec 14 | 2,116 | 222 | 301 | 0 |
| 30 Sep 14 | 2,087 | 226 | 301 | 0 |
| 30 Jun 14 | 2,027 | 261 | 301 | 0 |
| 31 Mar 14 | 1,944 | 300 | 301 | 0 |
| 31 Dec 13 | 1,819 | 300 | 305 | 0 |
Des revenus de qualité: EXPLEOSOL has high quality earnings.
Augmentation de la marge bénéficiaire: EXPLEOSOL's current net profit margins (9.5%) are lower than last year (14.3%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: EXPLEOSOL's earnings have grown significantly by 25.8% per year over the past 5 years.
Accélération de la croissance: EXPLEOSOL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: EXPLEOSOL had negative earnings growth (-28.2%) over the past year, making it difficult to compare to the IT industry average (12.9%).
Rendement des fonds propres
ROE élevé: EXPLEOSOL's Return on Equity (15.4%) is considered low.